The Susceptibility of AML with NPM1 Mutation for Immunotherapy

Acute myeloid leukemia (AML) with mutated nucleophosmin 1 (NPM1mut) forms a particular entity in the WHO classification of AML (WHO classification 2017). Overall survival in patients with AML with NPM1mut is more favorable, possibly based on the immunogenicity of the mutated NPM1. Thus, one can hypothesize that AML with NPM1mut might constitute an immunogenic subtype of AML. In a survival analyses of 25 NPM1mut AML we found that patients that appeared to have specific T-cell responses against one or two of the immunogenic peptides had a better overall survival in comparison to those cases showing no specific immune responses [1]. These findings show that immune responses against the mutated protein of NPM1 might contribute to the favourable prognosis of AML patients carrying NPM1mut. Clinical data also suggest that AML with NPM1mut correlates in general with better prognosis [2]; however, the underlying mechanisms still need to be further investigated
Author(s): Jochen Greiner, Michael Schmitt, Marlies Gotz, Markus Wiesneth, Hubert Schrezenmeier, Donald Bunjes, Hartmut Döhner, Lars Bullinger and Susanne Hofmann

Abstract | PDF

Share This Article